An ultrasensitive nano UHPLC-ESI-MS/MS method for the quantification of three neuromedin-like peptides in microdialysates

Bioanalysis

Volumn 7, Issue 5, 2015, Pages 605-619

  Maes, Katrien ^a   Béchade, Guillaume ^b   Van Schoors, Jolien ^a   Van Wanseele, Yannick ^a   Van Liefferinge, Joeri ^a   Michotte, Yvette ^a   Harden, Stephanie N ^c   Chambers, Erin E ^b   Claereboudt, Jan ^b   Smolders, Ilse ^a   Van Eeckhaut, Ann ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b WATERS CORPORATION   (United States)

^c Waters AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROMEDIN LIKE PEPTIDE DERIVATIVE; NEUROMEDIN N; NEUROPEPTIDE; NEUROTENSIN; UNCLASSIFIED DRUG; PEPTIDE; PEPTIDE FRAGMENT;

ACCURACY; ANALYTICAL PARAMETERS; ARTICLE; CHROMATOGRAPH; COLUMN CHROMATOGRAPHY; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEASIBILITY STUDY; IN VIVO STUDY; MASS SPECTROMETER; MICRODIALYSIS; ONLINE SYSTEM; PEPTIDE ANALYSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; MICRODIALYSIS; NEUROTENSIN; PEPTIDE FRAGMENTS; PEPTIDES; TANDEM MASS SPECTROMETRY;

EID: 84926339603     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.269     Document Type: Article

References (47)

1. Hokfelt T, Bartfai T, Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2(8), 463-472 (2003).
2. McGonigle P. Peptide therapeutics for CNS indications. Biochem. Pharmacol. 83(5), 559-566 (2012).
3. Baulac M, Pitkänen A. Research priorities in epilepsy for the next decade-a representative view of the European Scientific Community. Epilepsia 50, 571-578 (2008).
4. Minamino N, Sudoh T, Kangawa K, Matsuo H. Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides 6(Suppl. 3), 245-248 (1985).
5. Mori K, Miyazato M, Kangawa K. Neuromedin S. Discovery and functions. Results Probl. Cell Differ. 46, 201-212 (2008).
6. Almeida TA, Rojo J, Nieto PM et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr. Med. Chem. 11(15), 2045-2081 (2004).
7. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr. Opin. Endocrinol. Diabetes Obes. 15(1), 58-64 (2008).
8. Kitabgi P. Neurotensin and neuromedin N are differentially processed from a common precursor by prohormone convertases in tissues and cell lines. Results Probl. Cell Differ. 50, 85-96 (2010).
9. Mitchell JD, Maguire JJ, Davenport AP. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br. J. Pharmacol. 158(1), 87-103 (2009).
10. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 929, 161-179 (2013).
11. Howard JW, Kay RG, Pleasance S, Creaser CS. UHPLC for the separation of proteins and peptides. Bioanalysis 4(24), 2971-2988 (2012).
12. de Lange EC, de Boer AG, Breimer DD. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv. Drug Deliv. Rev. 45(2-3), 125-148 (2000).
13. Van Eeckhaut A, Maes K, Aourz N, Smolders I, Michotte Y. The absolute quantification of endogenous levels of brain neuropeptides in vivo using LC-MS/MS. Bioanalysis 3(11), 1271-1285 (2011).
14. Lanckmans K, Sarre S, Smolders I, Michotte Y. Quantitative liquid chromatography/mass spectrometry for the analysis of microdialysates. Talanta 74(4), 458-469 (2008).
15. Gruber SH, Angelucci F, Nomikos GG, Mathé AA. Effects of olanzapine on extracellular concentrations and tissue content of neurotensin in rat brain regions. Eur. Neuropsychopharmacol. 21(12), 918-927 (2011).
16. Lindström LH, Widerlöv E, Bisette G, Nemeroff C. Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophr. Res. 1(1), 55-59 (1988).
17. Breslin NA, Suddath RL, Bissette G, Nemeroff CB, Lowrimore P, Weinberger DR. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr. Res. 12(1), 35-41 (1994).
18. Sharma RP, Janicak PG, Bissette G, Nemeroff CB. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 154(7), 1019-1021 (1997).
19. Hertel P, Mathé JM, Nomikos GG, Iurlo M, Mathé AA, Svensson TH. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 72(1-2), 103-114 (1995).
20. Gruber SH, Nomikos GG, Mathé AA. Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat. Neuropsychopharmacology 26(5), 595-604 (2002).
21. Gruber SH, Nomikos GG, Mathé AA. d-Amphetamineinduced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors. J. Neurosci. Res. 69(1), 133-139 (2002).
22. Gruber SH, Nomikos GG, Mathé AA. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs. Eur. Neuropsychopharmacol. 16(8), 592-600 (2006).
23. Jalkanen AJ, Savolainen K, Forsberg MM. Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum. Neurosci. Lett. 502(2), 107-111 (2011).
24. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 872(1-2), 1-22 (2008).
25. Emmett MR, Andrén PE, Caprioli RM. Specific molecular mass detection of endogenously released neuropeptides using in vivo microdialysis/mass spectrometry. J. Neurosci. Methods 62(1-2), 141-147 (1995).
26. Haskins WEWang ZWatson CJ et al. Capillary LC-MS2 at the attomole level for monitoring and discovering endogenous peptides in microdialysis samples collected in vivo. Anal. Chem. 73(21) 5005-5014 (2001).
27. Li Q, Zubieta JK, Kennedy RT. Practical aspects of in vivo detection of neuropeptides by microdialysis coupled off-line to capillary LC with multistage MS. Anal. Chem. 81(6), 2242-2250 (2009).
28. Mabrouk OS, Kennedy RT. Simultaneous oxytocin and argvasopressin measurements in microdialysates using capillary liquid chromatography-mass spectrometry. J. Neurosci. Methods 209(1), 127-133 (2012).
29. Lanckmans K, Sarre S, Smolders I, Michotte Y. Use of a structural analogue versus a stable isotope labeled internal standard for the quantification of angiotensin IV in rat brain dialysates using nano-liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21(7), 1187-1195 (2007).
30. Andrén PE, Caprioli RM. Determination of extracellular release of neurotensin in discrete rat brain regions utilizing in vivo microdialysis/electrospray mass spectrometry. Brain Res. 845(2), 123-129 (1999).
31. Maes K, Van Liefferinge J, Viaene J et al. Improved sensitivity of the nano ultra-high performance liquid chromatographytandem mass spectrometric analysis of low-concentrated neuropeptides by reducing aspecific adsorption and optimizing the injection solvent. J. Chromatogr. A 1360, 217-228 (2014).
32. Maes K, Smolders I, Michotte Y, Van Eeckhaut A. Strategies to reduce aspecific adsorption of peptides and proteins in liquid chromatography-mass spectrometry based bioanalyses: An overview. J. Chromatogr. A, 1358C, 1-13 (2014).
33. John H, Walden M, Schafer S, Genz S, Forssmann WG. Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 378(4), 883-897 (2004).
34. Lanckmans K, Van Eeckhaut A, Sarre S, Smolders I, Michotte Y. Capillary and nano-liquid chromatography-tandem mass spectrometry for the quantification of small molecules in microdialysis samples: comparison with microbore dimensions. J. Chromatogr. A, 1131(1-2), 166-175 (2006).
35. Chervet JP, Ursem M, Salzmann JP. Instrumental requirements for nanoscale liquid chromatography. Anal. Chem. 68(9), 1507-1512 (1996).
36. Aubry A-F. LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays. Bioanalysis 3(16), 1819-1825 (2011).
37. Chambers EE, Lame ME, Bardsley J et al. High sensitivity LCMS/MS method for direct quantification of human parathyroid 1-34 (teriparatide) in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 938, 96-104 (2013).
38. EMA, Guideline on bioanalytical method validation. (2014) www.ema.europa.eu
39. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75(13), 3019-3030 (2003)
40. Paxinos G, Watson C. The Rat Brain in Stereotactic Coordinates (2nd Edition), American Press Inc., San Diego, USA (1986).
41. Chambers E.E. Webinar on protein and peptide therapeutics: addressing bioanalytical demands of complicated peptides. (2014) www.bioanalysis-zone.com
42. Williams JS, Donahue SH, Gao H, Brummel CL. Universal LC-MS method for minimized carryover in a discovery bioanalytical setting. Bioanalysis 4(9), 1025-1037 (2012)
43. Chambers EE, Legido-Quigley C, Smith N, Fountain KJ. Development of a fast method for direct analysis of intact synthetic insulins in human plasma: the large peptide challenge. Bioanalysis 5(1), 65-81 (2013).
44. Chambers EE, Fountain KJ, Smith N et al. Multidimensional LC-MS/MS enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma. Anal. Chem. 86(1), 694-702 (2014).
45. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2198-2207 (2009).
46. Schmerberg CM, Li L. Mass spectrometric detection of neuropeptides using affinity-enhanced microdialysis with antibody-coated magnetic nanoparticles. Anal. Chem. 85(2), 915-922 (2013).
47. Roy MC, Ikimura K, Nishino H, Naito T. A high recovery microsampling device based on a microdialysis probe for peptide sampling. Anal. Biochem. 399(2), 305-307 (2010).